INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALS The study investigated 123 metastatic ovarian ...
Parsortix platform shown to be compatible with the Roche BenchMark ULTRA automated staining system, with initial study of three key drug targets: HER2 (breast), TROP2 (lung) and PSMA (prostate) Roche ...
MILFORD, Mass., PLC Systems Inc., a company focused on innovative medical device technologies, announced today that it has received final approval from the U.S. Food and Drug Administration (FDA) to ...
Indivior Plc presents results from the phase 3 pivotal study of RBP-6000 buprenorphine monthly depot
* Indivior Plc - 24-week study met its primary and key secondary endpoints for both dosage regimens of RBP-6000 * Indivior - Clinical data from phase 3 study also showed outcomes with RBP-6000 are ...
* Strongbridge Biopharma Plc - phase 3 sonics study is now more than 80 percent enrolled and we remain on track to fully enroll study during Q2 * Strongbridge Biopharma Plc - on schedule to commence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results